Author of

• 28123

  +

  Best abstracts selected from submissions 3 (ID 3)

  • Event: ACLC 2018
  • Type: Oral Session
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 11/08/2018, 16:20 - 17:00, Crystal Ballroom 1

  • 28223

    +

    OA06 - Tepotinib in Non-Small Cell Lung Cancer with MET Exon 14-Skipping Mutations or MET Amplification: (ID 140)

    16:20 - 17:00  |  Author(s): P. Paik
    • Abstract

    Background:
    The MET pathway is frequently deregulated in human cancer, leading to dependency on MET signaling and hence this represents a potential therapeutic target in non-small cell lung cancer (NSCLC). MET alterations include MET exon 14-skipping mutations (METex14+) and MET amplification (METamp); these occur in ~3% and 0.4